Novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis

Publisher Website
Google Scholar
Abstract
Two patent applications claim novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis, that act via inhibition of the TNF-α-converting enzyme (TACE or ADAM-17). The hydrazides are claimed to be useful in the treatment of inflammatory diseases such as rheumatoid arthritis. The claimed sulphonylhydrazide and cyclic hydrazide derivatives both display comparable in vitro potency to Roche’s clinical development lead Ro 32-7315.

This publication has 3 references indexed in Scilit: